Brenda Thompson: Daily

New data reveals a stunning leap in hospital safety, saving 300,000 lives. Discover the tech and strategies behind this remarkable post-pandemic turnaround.

Nona Biosciences appoints a top AI mind to lead its A³ strategy, a bold move in the industry-wide race to automate drug discovery and outpace rivals.

Seattle-based Curi Bio secures strategic funding to scale its human-centric platforms, aiming to end the costly failures of traditional animal-based drug testing.

A new survey reveals a disconnect in menopause support, with a focus on mental health obscuring a costly metabolic crisis. Here’s why it matters.

A new AI platform is creating digital replicas of every clinical trial site, promising to slash drug development timelines and costs. Here's how.

Evestia Clinical's new advisory board is a bold move to dominate specialized CRO markets by combining deep therapeutic expertise with AI and global reach.

Adicet Bio's recent inducement grant is more than a routine hire. It’s a key move in biotech's talent war and a signal of its strategic future.

IASO Bio's CAR-T therapy approval in Hong Kong is more than a win for patients; it’s a validation of China's global biopharma ambitions.

An Israeli firm's MEMS-based device is expanding to 30+ countries, promising painless injections and a new era for aesthetics, vaccines, and medicine.

As Moleculin Biotech preps for a key investor address, its promising cancer drug Annamycin faces a critical race against mounting financial pressures.

FDA's nod for Otsuka's first-in-class IgAN drug ushers in a new era of targeted therapy, but the real test of its long-term promise is yet to come.

Wuzhou Special Paper teams with Valmet to build China's widest recycled board machine, signaling a major strategic shift in a booming market.

With fresh capital and a key acquisition, MiCare Path is scaling its AI-powered virtual care platform, signaling a major shift in the health tech market.

With a breakthrough FDA submission for an AI that detects double-digit conditions at once, Aidoc is betting on its foundation model and proven OS.

Pasithea Therapeutics secured a $1M grant from the ALS Association for its novel drug, PAS-004. Can this new MEK inhibitor open a new front against ALS?

A Chinese biotech's novel bispecific, dual-payload ADCs just secured $60M. Here’s how this new class of therapy aims to outsmart resistant tumors.

The 11th annual Wings to Cure Gala, sponsored by Alex and Danielle Samoylovich, aims to accelerate groundbreaking cancer research at Northwestern's Lurie Cancer Center while honoring the memory of a beloved friend and business partner.

Anthony Tassi steps into the CEO role at Good+Foundation as families face economic headwinds. His background in literacy and scaling programs positions the nonprofit for expanded impact.

A $1 million donation from Excelis Medical Associates fuels the construction of a new, state-of-the-art children’s hospital in Tampa Bay, promising expanded pediatric care and research for the region.

A $2M investment will bolster St. Michael’s Hospital’s innovative programs addressing critical health inequities for Toronto’s most vulnerable populations, expanding embedded outreach and social prescribing.